Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
06 2023
Historique:
received: 08 10 2022
accepted: 16 12 2022
revised: 13 12 2022
medline: 8 6 2023
pubmed: 8 1 2023
entrez: 7 1 2023
Statut: ppublish

Résumé

SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA-mutant, hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC) patients. We report here real-life data of patients prospectively registered in the French alpelisib early access program (EAP) opened to PIK3CA-mutant HR+/HER2- ABC patients treated with alpelisib and fulvestrant. Primary endpoint was PFS by local investigators using RECIST1.1. Eleven centers provided individual data on 233 consecutive patients. Patients had received a median number of 4 (range: 1-16) prior systemic treatments for ABC, including CDK4/6 inhibitor, chemotherapy, fulvestrant and everolimus in 227 (97.4%), 180 (77.3%), 175 (75.1%) and 131 (56.2%) patients, respectively. After a median follow-up of 7.1 months and 168 events, median PFS was 5.3 months (95% CI: 4.7-6.0). Among 186 evaluable patients, CBR at 6 months was 45.3% (95% CI: 37.8-52.8). In multivariable analysis, characteristics significantly associated with a shorter PFS were age < 60 years (HR = 1.5, 95% CI = 1.1-2.1), >5 lines of prior treatments (HR = 1.4, 95% CI = 1.0-2.0) and the C420R PI3KCA mutation (HR = 4.1, 95% CI = 1.3-13.6). N = 91 (39.1%) patients discontinued alpelisib due to adverse events. To our knowledge, this is the largest real-life assessment of alpelisib efficacy. Despite heavy pre-treatments, patients derived a clinically relevant benefit from alpelisib and fulvestrant.

Identifiants

pubmed: 36611120
doi: 10.1038/s41388-022-02585-3
pii: 10.1038/s41388-022-02585-3
doi:

Substances chimiques

Fulvestrant 22X328QOC4
Alpelisib 08W5N2C97Q
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Receptor, ErbB-2 EC 2.7.10.1
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1951-1956

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol J Am Soc Clin Oncol. 2011;29:4452–61.
doi: 10.1200/JCO.2010.34.4879
Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7:283ra51.
doi: 10.1126/scitranslmed.aaa4442 pubmed: 25877889 pmcid: 4433148
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31:377–86.
doi: 10.1016/j.annonc.2019.11.006 pubmed: 32067679
Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, et al. The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis. J Cell Biochem. 2018;119:4287–92.
doi: 10.1002/jcb.26687 pubmed: 29345357 pmcid: 5995110
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13:1117–29.
doi: 10.1158/1535-7163.MCT-13-0865 pubmed: 24608574
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40.
doi: 10.1056/NEJMoa1813904 pubmed: 31091374
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol J Eur Soc Med Oncol. 2020;31:1623–49.
doi: 10.1016/j.annonc.2020.09.010
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489–98.
doi: 10.1016/S1470-2045(21)00034-6 pubmed: 33794206
Patil S. Early access programs: Benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016;7:4.
doi: 10.4103/2229-3485.173779 pubmed: 26955570 pmcid: 4763516
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol J Eur Soc Med Oncol. 2021;32:208–17.
doi: 10.1016/j.annonc.2020.11.011
Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:JCO.22.00338.
Barrios MSDM, Wang DG, Blinder VS, Bromberg J, Drullinsky P, Funt SA, et al. Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients. J Clin Oncol. 2020;38:1063–1063.
doi: 10.1200/JCO.2020.38.15_suppl.1063
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026 pubmed: 19097774

Auteurs

D Bello Roufai (D)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France. Diana.belloroufai@curie.fr.

A Gonçalves (A)

Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France.

T De La Motte Rouge (T)

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.

S Akla (S)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

C Blonz (C)

Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France.

J Grenier (J)

Department of Medical Oncology, Institut du Cancer d'Avignon, Avignon, France.

J Gligorov (J)

Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France.
INSERM U938, Institut Universitaire de Cancérologie, AP-HP Sorbonne Université, Paris, France.

M Saghatchian (M)

Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.

C Bailleux (C)

Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.

H Simon (H)

Department of Medical Oncology, University Hospital of Brest, Brest, France.

I Desmoulins (I)

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Z Tharin (Z)

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

E Renaud (E)

Department of Medical Oncology, University Hospital of Brest, Brest, France.

M Bertho (M)

Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France.

M-A Benderra (MA)

Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France.

S Delaloge (S)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

L Robert (L)

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.

P Cottu (P)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.

J Y Pierga (JY)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.
Paris Cité University, Paris, France.

D Loirat (D)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.

A Bertucci (A)

Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France.

B Renouf (B)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.

F C Bidard (FC)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.
UVSQ, Paris-Saclay University, Saint Cloud, France.

F Lerebours (F)

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH